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Abstract
Levels of soluble tumour necrosis factor receptors (sTNFRs) are
elevated in the circulation of patients with rheumatoid arthritis
(RA). Although these receptors can act as natural inhibitors of
tumour necrosis factor-α, levels of sTNFRs in RA appear to be
insufficient to prevent tumour necrosis factor-α induced
inflammation. The factors that regulate circulating levels of
sTNFRs are unclear, but polymorphisms in the tumour necrosis
factor receptor genes may play a role. We investigated the
relationship between polymorphisms in the tumour necrosis
factor receptor I (TNF-RI) and II (TNF-RII) genes and levels of
sTNFRs in two groups of Caucasian RA patients: one with early
(disease duration ≤2 years; n = 103) and one with established
disease (disease duration ≥5 years; n = 151). PCR restriction
fragment length polymorphism analysis was used to genotype
patients for the A36G polymorphism in the TNF-RI gene and the
T676G polymorphism in TNF-RII. Levels of sTNFRs were
measured using ELISA. We also isolated T cells from peripheral
blood of 58 patients with established RA with known TNF-R
genotypes, and release of sTNFRs into the culture medium was
measured in cells incubated with or without
phytohaemagglutinin. Serum levels of the two sTNFRs (sTNF-RI
and sTNF-RII) were positively correlated in both populations,
and the level of each sTNFR was significantly higher in the
patients with established disease (P  < 0.0001). Multiple
regression analyses corrected for age, sex and disease duration
revealed a significant trend toward decreasing sTNF-RI and
sTNF-RII levels across the TNF-RII genotypes (TT > TG > GG)
of patients with established disease (P for trend = 0.01 and P
for trend = 0.03, respectively). A similar nonsignificant trend was
seen for early disease. No relationship with the TNF-RI A36G
polymorphism was observed. sTNFRs released by isolated T
cells exhibited a similar trend toward decreasing levels
according to TNF-RII genotype, although only the association
with levels of sTNF-RII was significant. Strong correlations were
found between levels of circulating sTNFRs and levels released
by T cells in vitro. Our data indicate that the T676G
polymorphism in TNF-RII is associated with levels of sTNFRs
released from peripheral blood T cells, and with circulating
levels of sTNFR in patients with RA.
Introduction
Tumour necrosis factor (TNF)-α is a pleiotropic cytokine that is
important in the pathogenesis of rheumatoid arthritis (RA), in
which it plays a role in cartilage degradation, bone resorption,
adhesion molecule expression, leucocyte infiltration, enzyme
production and cytokine synthesis (see reviews by Brennan
and coworkers [1] and Choy and Panayi [2]). The actions of
TNF-α are mediated through binding to two distinct cell sur-
face receptors, namely tumour necrosis factor receptor I (TNF-
RI) and II (TNF-RII) [3,4]. Both are transmembrane glycopro-
teins with a three domain structure: a multiple cysteine-rich
motif bearing an extracellular domain that facilitates ligand
binding; a hydrophobic membrane spanning domain; and an
intracellular domain that mediates signal transduction. The
receptor molecules share significant homology in their extra-
cellular domains but they have distinct intracellular domains
[5]. Most significantly, TNF-RI, but not TNF-RII, possesses a
death domain that can transduce the signal for cell death [6].
ELISA = enzyme-linked immunosorbent assay; HAQ = health assessment questionnaire; NF-κB = nuclear factor-κB; PCR = polymerase chain reac-
tion; PHA = phytohaemagglutinin; RA = rheumatoid arthritis; SNP = single nucleotide polymorphism; sTNFR = soluble tumour necrosis factor recep-
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The two receptors appear to promote distinct TNF-α-induced
cellular responses, although both are capable of inducing the
nuclear factor-κB (NF-κB) and apoptotic pathways [7-10],
providing some evidence of receptor function redundancy.
In addition to membrane bound forms, both TNF receptors can
exist as soluble proteins. These are soluble variants of the
extracellular domains [11-13] and are derived from the mem-
brane bound form by the proteolytic actions of a disintegrin
metalloproteinase called TNF-α converting enzyme (TACE)
[14]. They retain their ligand binding capacity after cleavage
[11,13] and can act as natural inhibitors of TNF-α by seques-
tering soluble TNF-α and preventing it from binding to mem-
brane-bound TNF receptor. The levels of soluble TNF
receptors (sTNFRs) are elevated in the serum and synovial
fluid of RA patients [15-17], but these levels appear to be
insufficient to prevent the chronic inflammation promoted by
TNF-α [16]. Furthermore, the expression of membrane-bound
TNF receptor is increased on a variety of cells in RA synovium
[18,19], facilitating prolonged TNF-α signalling and the contin-
uation of TNF-α regulated processes. The factors that regulate
the levels of sTNFR are unclear, but polymorphisms within the
TNF receptor genes may play a role.
The genes encoding TNF-RI and TNF-RII have been mapped
to chromosomes 12p13 and 1p36, respectively [20]. Numer-
ous polymorphisms are present in these genes [21-23] and
some have been investigated for their association with RA [24-
30]. An association has been reported between a single nucle-
otide polymorphism (SNP) in exon 6 (T676G) of the TNF-RII
gene and susceptibility to familial but not sporadic RA [24,25].
Two studies in sporadic RA showed no association between
the T676G polymorphism in the TNF-RII gene and RA severity
[27,29], although one report has suggested an association
with functional severity [28]. The A36G polymorphism in exon
1 of the TNF-RI gene has been associated with a protective
role in familial RA [30].
In this study we report that polymorphism in the TNF-RII gene,
but not the TNF-RI gene, is associated with circulating levels
of TNF receptors in a population of Caucasian RA patients,
and that this polymorphism is also associated with levels of
sTNFRs released in vitro by isolated T cells from RA patients.
Materials and methods
Patients
Two groups of Caucasian RA patients were studied. The first
group had early disease (duration ≤2 years; n = 103) and the
second had established disease (duration ≥5 years; n = 151;
Table 1). The patients were all of British origin and resident in
North Staffordshire, England, and satisfied the 1987 American
College of Rheumatology criteria for RA [31]. All patients were
receiving anti-inflammatory and/or antirheumatic therapy, with
the majority of patients with established disease (>90%)
being treated with one or more disease-modifying antirheu-
matic drugs. Steroids and cytotoxic drugs such as azathio-
prine or cyclophosphamide were being received by a small
minority of individuals (<5%). No patients were being treated
with anti-TNF-α agents. Radiographic damage was measured
by scoring radiographs of the hands and feet using the method
proposed by Larsen and coworkers [32], and functional out-
come was assessed using the Health Assessment Question-
naire (HAQ) [33]. In patients with early RA, HAQ
measurements were taken at recruitment into the study and at
5 years of follow up.
Serum, separated from clotted peripheral blood (5 ml) from
each patient, was stored at -70°C until required for measure-
ment of sTNFRs. Synovial fluid was also collected from 45
patients who presented with knee effusions at the time of
blood collection. Fluids were centrifuged and separated from
the resulting cell pellet, before storage at -70°C. The study
was approved by the North Staffordshire local research ethics
committee.
Table 1
Characteristics of the two rheumatoid arthritis patient populations
Population Early disease Established disease
Number 103 151
Male/Female (n) 44/59 63/88
Age (years; mean ± SD) 55.0 ± 13.4 60.2 ± 11.1
Age at onset (years; mean ± SD) 54.3 ± 13.4 46.6 ± 12.1
Disease duration (years; mean ± SD) 0.7 ± 0.5 13.7 ± 6.3
Rheumatoid factor ever positive (%) 52/92 (56.5) 86/126 (68.3)
Nodule positive (%) 4/102 (3.9) 28/150 (18.7)
SD, standard deviation.Available online http://arthritis-research.com/content/7/6/R1227
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Cell isolation and culture
T cells were isolated from fresh peripheral blood samples (4
ml) from RA patients with established disease (n = 58). Cell
isolation was by negative selection using a modified density
gradient centrifugation technique that utilizes novel tetrameric
antibody complexes (RosetteSep; Stemcell Technologies Inc.,
Vancouver, Canada). Isolated T cells (2 × 105 cells/200 µl)
were cultured in RPMI 1640 synthetic culture medium supple-
mented with 10% heat-inactivated foetal bovine serum, 100
units/ml penicillin, 100 µg/ml streptomycin and 10% autolo-
gous serum, in 96-well cell culture plates. Cultures were incu-
bated, with or without phytohaemagglutinin (PHA; 10 µg/ml),
at 37°C in a 5% carbon dioxide humidified air environment for
48 hours. Cell supernatants were then harvested and stored
at -20°C until required for analysis of sTNFR levels.
Genomic DNA isolation
Peripheral blood samples (4 ml) collected in EDTA tubes were
obtained from each patient and were stored at -20°C. After
thawing at 37°C, the genomic DNA was isolated using a
DNAce MegaBlood Kit procedure as directed by the manufac-
turer (Bioline, London, UK).
PCR primers
The following primer sequences were used to amplify a 183
base pair fragment containing the SNP at nucleotide 36 in
exon 1 of the TNF-RI gene [21]: forward 5'-GAG CCC AAA
TGG GGG AGT GAG AGG-3', and reverse 5'-ACC AGG
CCC GGG CAG GAG AG-3'.
A 242 base pair fragment containing the SNP at nucleotide
676 in exon 6 of the TNF-RII gene was amplified with the fol-
lowing primer sequences [34]: forward 5'-ACT CTC CTA
TCC TGC CTG CT-3'; and reverse 5'-TTC TGG AGT TGG
CTG CGT GT-3'.
PCR amplification and single nucleotide polymorphism 
genotyping
The fragment of interest from each of the TNF receptor genes
was amplified using an identical reaction mixture and condi-
tions that were described previously [27]. All amplification
reactions were performed in a Flexigene Thermal Cycler unit
(Techne [Cambridge] Limited, Cambridge, UK) using a 96-
well, full-skirt heating block. During amplification wells were
capped with PCR cap strips. Following amplification the prod-
ucts were stored at 4°C until required for genotyping by
restriction fragment length polymorphism analysis [27].
ELISA
Serum, synovial fluid and T cell supernatant levels of sTNF-RI
and sTNF-RII were quantified using the respective Duoset
ELISA Development Kit as directed by the manufacturer (R&D
Systems Europe, Abingdon, UK). For determination of sTNF-
RI levels, sera, synovial fluids and T-cell supernatants were
diluted 1:10, 1:50 and 1:3, respectively. For soluble TNF-RII,
sera, synovial fluids and T-cell supernatants were diluted 1:20,
1:80 and 1:4, respectively. All samples were run in duplicate
with the appropriate standards on 96-well microplates.
Statistical analysis
The relationship between the two sTNFRs was assessed
using Spearman's rank correlation, whereas differences in
sTNFR levels between early and established RA were
assessed using the Mann–Whitney U-Test. Multiple regres-
sion analysis was used to assess the relationship between
each sTNFR and age (corrected for sex and disease duration),
and between the TNF receptor genotypes and sTNFR levels
(corrected for age, sex and disease duration). Where neces-
sary the data were normalized by logarithmic transformation
before analysis. All data were analyzed using the Number
Cruncher Statistical Software package for Windows (NCSS
2000, NCSS Statistical Software, Kaysville, Utah, USA) P <
0.05 were considered statistically significant.
Results
sTNFR levels in rheumatoid arthritis
Both sTNFRs were detected in the sera of all patients studied.
Consistent with the findings reported by Cope and coworkers
[16], levels of sTNF-RII were approximately three times greater
on average than those of sTNF-RI. A strong positive correla-
tion was observed between the levels of the two sTNFRs in
both patient populations (Rs > 0.45; P < 0.0001). The levels
of each sTNFR were also found to increase significantly with
age in both patient groups (P < 0.0001), and this was inde-
pendent of disease duration. Similar associations between
sTNFR levels and age were seen in male and female patients
(data not shown). Also, the median level of each sTNFR was
significantly higher in patients with established disease than in
those with early disease (P  < 0.0001); this association
remained after correction for age.
TNF-RI A36G single nucleotide polymorphism and 
sTNFR serum levels
The A36G SNP genotype frequencies in each population and
the respective mean levels of both sTNFRs are shown in Table
2. The observed allele frequencies for the A and G alleles were
64.1% and 35.9%, respectively, in the early RA population
and 55.0% and 45.0% in the established RA population. The
allele and genotype frequencies are broadly comparable to
those reported elsewhere [24,27,30], although there is a sug-
gestion from this study that the GG genotype is more frequent
in patients with established disease. There were no significant
differences in the serum levels of either sTNFR between the
three genotypes in patients with early disease or with estab-
lished disease (Table 2). This finding was also observed when
the two populations were combined and the analysis repeated
(data not shown).Arthritis Research & Therapy    Vol 7 No 6    Glossop et al.
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TNF-RII T676G single nucleotide polymorphism and 
sTNFR serum levels
The genotype and sTNFR level data for the T676G polymor-
phism in patients with early and established disease are
shown in Table 3. The T and G alleles had frequencies of
77.2% and 22.8%, respectively, in both the early and
established disease populations, and these frequencies were
similar to those previously reported [24-29]. In established RA,
analysis by multiple regression with correction for age, sex and
disease duration revealed a significant association between
TNF-RII genotype and the levels of sTNF-RI (P for trend =
0.01) and sTNF-RII (P for trend = 0.03) in the order TT > TG
> GG. An identical trend was seen for levels of sTNF-RI and
sTNF-RII in patients with early disease, although these associ-
ations were not significant (P = 0.3 and P = 0.055, respec-
tively). In addition, the levels of sTNF-RI and sTNF-RII were
significantly associated with TNF-RII genotype (P for trend =
0.02 and P for trend = 0.01, respectively) when the two pop-
ulations were combined and analyzed by multiple regression
with correction for age, sex and disease duration.
TNF receptor polymorphisms and sTNFR synovial fluid 
levels
Synovial fluids collected at the same time as sera were availa-
ble in 45 patients. Mean levels of sTNF-RI and sTNF-RII in the
synovial fluids were significantly higher (7,736 and 18,120 pg/
ml, respectively) than in the paired sera, but there was no
direct correlation between levels in the synovial fluid and
serum. No association was found between synovial fluid
sTNFR levels and the A36G TNF-RI or 676G TNF-RII geno-
types (data not shown).
TNF receptor polymorphisms and clinical outcome 
measures
We showed previously that polymorphisms in the TNF-RI and
TNF-RII genes were not associated with radiographic or func-
tional severity in a cross-sectional study of patients with RA
[27]. Similar findings were later reported by van der Helm-van
Mil and coworkers [29], although another study by Constantin
and colleagues [28] suggested an association of the TNF-RII
G allele with worse functional (HAQ) outcome in early RA
patients followed up for 5 years.
In the present study we again found no association between
TNF-RI or TNF-RII polymorphisms and cross-sectional meas-
ures of radiographic or functional severity in patients with early
or established disease (data not shown). In a similar manner to
that reported by Constantin and coworkers [28], we also
investigated the association between the TNF-RII polymor-
phism and functional severity of the early RA patients exam-
ined at baseline and at 5 years follow up. There was no
significant difference in HAQ scores between patients with
and those without the G allele at baseline (1.41 versus 1.60;
P = 0.1) or after 5 years of follow up (1.41 versus 1.50; P =
0.9). There was also no significant difference in HAQ score
progression.
Analysis of other clinical parameters associated with disease
severity (extra-articular disease/nodules, rheumatoid factor,
surgery, mechanical joint score, etc.) revealed no differences
between TNF-RII genotypes (data not shown). However, in a
separate study on anaemia in RA, involving many of these
Table 2
TNF-RI A36G single nucleotide polymorphism genotype 
frequencies and sTNFR levels
Genotype n (%) sTNF-RI (pg/ml) sTNF-RII (pg/ml)
Early RA
AA 41 (39.8) 1,543 ± 597 4,435 ± 1,898
AG 50 (48.5) 1,426 ± 629 4,302 ± 1,672
GG 12 (11.7) 1,303 ± 447 4,566 ± 1,490
Established RA
AA 48 (31.8) 1,827 ± 758 5,740 ± 1,942
AG 70 (46.4) 1,688 ± 674 5,475 ± 2,020
GG 33 (21.8) 1,757 ± 559 5,857 ± 2,393
Shown are tumor necrosis factor receptor I (TNF-RI) A36G single 
nucleotide polymorphism genotype frequencies and soluble tumor 
necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) 
patients with early (n = 103) and established (n = 151) disease. 
sTNFR levels are expressed as the mean ± standard deviation. No 
significant differences in sTNFR levels were found between any of 
the genotypes in either population. sTNF-RII, soluble tumor necrosis 
factor receptor II.
Table 3
TNF-RII T676G single nucleotide polymorphism genotype 
frequencies and sTNFR levels
Genotype n (%) sTNF-RI (pg/ml) sTNF-RII (pg/ml)
Early RA
TT 63 (61.2) 1,503 ± 704 4,690 ± 1,961
TG 33 (32.0) 1,451 ± 370 3,961 ± 1,242
GG 7 (6.8) 1,094 ± 240 3,648 ± 697
Established RA
TT 91 (60.3) 1,816 ± 705 5,837 ± 2,219
TG 51 (33.7) 1,633 ± 642 5,375 ± 1,921
GG 9 (6.0) 1,700 ± 570 5,187 ± 1,066
Shown are tumour necrosis factor receptor II (TNF-RII) T676G single 
nucleotide polymorphism (SNP) genotype frequencies and soluble 
tumour necrosis factor receptor (sTNFR) levels in rheumatoid arthritis 
(RA) patients with early (n = 103) and established (n = 151) disease. 
sTNFR levels are expressed as the mean ± standard deviation. 
Multiple regression analyses of log transformed data corrected for 
age, sex and disease duration revealed a significant trend of 
decreasing soluble tumour necrosis factor receptor I (sTNF-RI) and 
sTNF-RII levels across the genotypes (order: TT > TG > GG) of 
patients with established disease (P for trend = 0.01 and P for trend 
= 0.03, respectively). A similar nonsignificant trend was seen for 
patients with early disease (P = 0.3 and P = 0.055, respectively).Available online http://arthritis-research.com/content/7/6/R1227
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patients, we reported an association between carriage of the
TNF-RII T allele and anaemia of chronic disease [35].
TNF receptor polymorphisms and levels of sTNFR 
released by isolated T cells
We investigated whether there was any association between
polymorphism in the TNF receptor genes and levels of sTNFRs
released into the culture medium of unstimulated and stimu-
lated T cells from RA patients. No association was found
between the TNF-RI A36G polymorphism and levels of
sTNFRs released (data not shown). However, a significant
trend was found in levels of sTNF-RII released into culture
medium by both unstimulated and stimulated T cells according
to the TNF-RII genotype in the order TT > TG > GG (unstimu-
lated and stimulated, respectively:P for trend = 0.049 and P
for trend = 0.02; Table 4). Similar trends for release of sTNF-
RI were seen in unstimulated and stimulated T cells, although
these did not achieve statistical significance.
Relationship between circulating levels of sTNFR and in 
vitro release from T cells
We examined whether the levels of sTNFRs in the circulation
of RA patients were reflected in the levels of sTNFRs released
by peripheral blood T cells in vitro. Strong correlations were
found between serum levels of both sTNFRs and levels of
these receptors released from isolated T cells (Table 5). The
circulating levels of each sTNFR were strongly correlated with
levels released by both unstimulated and stimulated T cells.
Discussion
We investigated whether SNPs in the TNF receptor genes are
associated with circulating levels of the naturally occurring sol-
uble form of these receptor molecules in patients with early
and established RA. We report evidence of an association
between the T676G polymorphism in TNF-RII and serum
levels of both sTNF-RI and sTNF-RII in patients with estab-
lished disease, with a trend toward decreasing levels across
the genotypes in the order TT > TG > GG. An identical trend
was observed in patients with early disease, although the data
failed to reach statistical significance. There was no evidence
of any association between the TNF-RI A36G polymorphism
and the levels of either sTNFR, in early or established RA.
No association was found between TNF receptor genotypes
and synovial fluid levels of sTNFRs. This is probably not sur-
prising because no correlation was found between synovial
fluid and serum levels of sTNFRs, which is consistent with pre-
vious data [17]. We suggest that the high levels of sTNFRs
seen in synovial fluids reflect the high degree of local
inflammation, where genetic regulation of sTNFR levels by the
TNF-RII gene is likely to have less impact than other factors in
such an inflammatory environment. In contrast, the levels seen
in the circulation are more likely to reflect genetic regulation of
sTNFR levels, because any genetic influence is less likely to be
overwhelmed by inflammatory factors.
Our finding of an association between the TNF-RII polymor-
phism and circulating levels of sTNFRs is reinforced by our in
vitro studies, which show an identical trend in the release of
sTNFRs, according to genotype, by isolated T cells from RA
patients. We also demonstrated that the levels of sTNFR
released by T cells in vitro are very closely correlated with the
levels of circulating sTNFRs in these patients. Release of
sTNFRs was greatest in T-cell cultures from patients carrying
the TNF-RII TT genotype. The same trend was seen both in
unstimulated and PHA stimulated cells, although the associa-
tion with TNF-RII genotype was significant only for levels of
sTNF-RII.
Table 4
Association between TNF-RII T676G single nucleotide 
polymorphism genotype and sTNFR levels released by T cells
Genotype n (%) sTNF-RI (pg/ml) sTNF-RII (pg/ml)
Unstimulated T cells
TT 38 (65.5) 166.8 ± 57.8 582.2 ± 259.6
TG 15 (25.9) 144.1 ± 78.2 428.1 ± 222.3
GG 5 (8.6) 137.2 ± 68.9 398.8 ± 194.9
Stimulated T cells
TT 38 (65.5) 178.0 ± 57.9 998.3 ± 355.6
TG 15 (25.9) 146.5 ± 75.5 769.5 ± 292.8
GG 5 (8.6) 141.6 ± 75.7 724.4 ± 167.3
Shown is the association between tumour necrosis factor receptor II 
(TNF-RII) T676G single nucleotide polymorphism genotype and 
soluble tumour necrosis factor (sTNFR) levels released by T cells 
isolated from rheumatoid arthritis (RA) patients (n = 58). sTNFR 
levels are expressed as mean ± standard deviation. Levels of sTNFR 
released into culture medium of isolated T cells exhibited a similar 
trend of decreasing levels of both receptors according to TNF-RII 
genotype (order: TT > TG > GG), although only the associations 
with sTNF-RII were significant (unstimulated and stimulated cells, 
respectively: P for trend = 0.049 and P for trend = 0.02; multiple 
regression analysis corrected for age, sex and disease duration). 
sTNF-RI, soluble tumor necrosis factor receptor I.
Table 5
Correlation between serum levels of sTNFR and levels released 
by isolated T cells
Serum levels Unstimulated T cells Stimulated T cells
sTNF-RI sTNF-RII sTNF-RI sTNF-RII
sTNF-RI 0.883 0.818 0.858 0.692
sTNF-RII 0.865 0.923 0.837 0.763
Shown is the correlation between serum levels of soluble tumour 
necrosis factor receptor (sTNFR) and levels released by isolated T 
cells from rheumatoid arthritis (RA) patients (n = 58). Spearman 
correlation coefficients are shown. P < 0.0001 for all correlations. 
sTNF-RI, soluble tumor necrosis factor receptor I; sTNF-RII, soluble 
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We also measured sTNFR release by isolated monocytes in
vitro and found a similar relationship between sTNFR levels
and TNF-RII genotype in cells stimulated with or without
lipopolysaccharide. However, this did not reach significance,
and the correlation between TNF receptor levels released by
monocytes and serum levels was weaker than for T cells
(unpublished observations). In multiple regression analyses of
serum TNF receptor levels, which included levels released by
T cells and monocytes as independent variables, we found
that only levels released by T cells were associated with serum
levels (unpublished observations).
The association of the TNF-RII T676G polymorphism with cir-
culating sTNF-RII levels is consistent with a previous study
[36] that demonstrated higher levels of sTNF-RII in healthy
individuals carrying a T allele. However, the association with
sTNF-RI levels was unexpected because the two TNF recep-
tor genes are encoded on separate chromosomes. It is not
clear how polymorphism within the TNF-RII gene might influ-
ence levels of sTNF-RI, although the strong correlation
between the levels of these soluble receptors indicates that
their production and/or release are closely linked.
The T676G polymorphism in exon 6 of the TNF-RII gene
occurs within the fourth cysteine-rich domain of the extracellu-
lar domain, close to a point where the proteolytic cleavage site
for TACE is thought to lie [37]. The polymorphism results in a
nonconservative amino acid substitution in which arginine,
with a highly basic side chain, replaces methionine, which has
a nonpolar side chain (methionine → arginine, M196R). The
location and nature of this polymorphism suggests the possi-
bility that processing of membrane bound TNF-RII by TACE
might be affected. However, functional analysis of this poly-
morphism in TNF-RII transfected HeLa cells revealed no
effects on the release of soluble receptors from the cell sur-
face, nor any effect on physical binding parameters [38]. In
contrast, our findings suggest that this polymorphism may play
a role in the regulation of soluble receptor release in T cells.
However, the possibility that the association is with another
polymorphism in linkage disequilibrium cannot be ruled out.
Recently, the TNF-RII 196R variant was shown to have a sig-
nificantly lower ability to induce direct NF-κB signalling via
TNF-RII and to enhance TNF-RI dependent TNF-α induced
apoptosis [39]. The diminished ability of the 196R variant to
induce NF-κB activation is paralleled by a diminished induc-
tion of NF-κB dependent target genes involved in antiapop-
totic or proinflammatory functions. It is possible that in certain
cell types or under particular experimental conditions that the
reduced ability of the 196R variant to induce NF-κB
dependent genes may lead to reduced release of sTNFRs
(e.g. through lower production of proteins that are important in
regulating the cleavage and release of these receptors).
The mean serum levels of sTNF-RII were approximately three
times greater than for sTNF-RI in each patient population. The
levels of sTNF-RII in culture medium from unstimulated T cells
were also about three times greater than those of sTNF-RI,
although this increased to approximately five times greater
after stimulation of T cells with PHA. This can be explained by
increased release of sTNF-RII, but not of sTNF-RI, after PHA
stimulation. This is similar to the situation previously observed
in lipopolysaccharide stimulated monocytes and alveolar mac-
rophages, in which sTNF-RII but not sTNF-RI release was
enhanced after stimulation [40,41]. These differences in solu-
ble receptor release may have important consequences for
TNF-α signalling (e.g. increased release of sTNF-RII may
reduce the ability of cells to be activated by interactions with
membrane bound TNF-α on surrounding cells) [42]. Localized
differences in the concentrations of soluble receptors may
also have significant effects on inhibition or promotion of TNF-
α activity, depending on the tissue compartment and the level
of TNF-α present.
Previous studies in healthy individuals reported an age associ-
ated significant increase in serum levels of both sTNFRs
[43,44], whereas a study conducted in RA patients failed to
identify any correlation between sTNFR levels and age [16]. In
another study conducted in healthy individuals [45] the levels
of sTNF-RII were lower in older (50–67 years) than in younger
individuals (25–35 years). In both populations studied here,
we found a highly significant association between increasing
levels of both sTNFRs and age, which was independent of dis-
ease duration. An explanation for these conflicting data is not
yet evident.
The clinical relevance of our findings is unclear at present, but
it has been shown that familial susceptibility to RA is associ-
ated with the TNF-RII G allele and particularly the GG geno-
type [24,25], which was associated with the lowest sTNF-RII
levels in our study. It is possible that lower levels of sTNFRs
may contribute to the development of RA if a particular thresh-
old of TNF-α activity is exceeded in genetically susceptible
individuals. Genetic regulation of TNF receptor levels may also
influence the long-term outcome of the disease and response
to anti-TNF-α therapy. There is some evidence that individuals
carrying the TNF-RII G allele exhibit poorer response to anti-
TNF-α therapy [46]. Constantin and coworkers [28] also sug-
gested that the G allele is associated with worse functional
outcome, based on 5 years of follow up of early RA patients,
although we did not find an association in a previous cross-
sectional study [27] and could not confirm the findings of
those investigators in the present study. Therefore, the associ-
ation of the TNF-RII T676G polymorphism with functional
severity is uncertain. However, we have provided recent evi-
dence that the T allele (associated with higher sTNFR serum
levels and increased release from T cells in the present study)
may be associated with anaemia of chronic disease in RA [35].
Compared with nonanaemic patients, those with anaemia ofAvailable online http://arthritis-research.com/content/7/6/R1227
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chronic disease also have serum levels of sTNF-RI and sTNF-
RII that are about 30% higher (P ≤ 0.007), which is consistent
with the T allele association.
Although the differences in sTNFR serum levels between TNF-
RII genotypes are not large, it is noteworthy that exactly the
same trend was seen throughout for serum levels in early and
established RA, and for unstimulated and stimulated T-cell cul-
tures. Several studies have shown that circulating sTNFR lev-
els and/or polymorphisms in the TNF-RII gene are associated
with heart failure, hypertension, obesity and insulin resistance,
and differences in serum levels of a similar magnitude to those
found in this study were shown to be clinically relevant in these
conditions [47-52]. Our findings may thus be of particular
importance in RA, in which there is evidence of increased risk
for cardiovascular disease and metabolic syndrome abnormal-
ities [53].
Conclusion
Our results indicate that there is an association between the
T676G SNP in the TNF-RII gene and levels of sTNFRs
released by T cells of RA patients. This finding is reinforced by
an association between this polymorphism and circulating lev-
els of sTNFRs in established RA. Although various inflamma-
tory factors may influence the release of TNF receptors, our
data indicate that genetic regulation involving the TNF-RII
gene may play some role in determining circulating levels in
RA.
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